177 related articles for article (PubMed ID: 29316377)
1. Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta-Analysis.
Hresko A; Lin TC; Solomon DH
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1431-1438. PubMed ID: 29316377
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
[TBL] [Abstract][Full Text] [Related]
4. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients.
Mennini FS; Marcellusi A; Gitto L; Iannone F
Clin Drug Investig; 2017 Apr; 37(4):375-386. PubMed ID: 28074337
[TBL] [Abstract][Full Text] [Related]
6. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
Neubauer AS; Minartz C; Herrmann KH; Baerwald CGO
Clin Exp Rheumatol; 2018; 36(3):448-454. PubMed ID: 29303709
[TBL] [Abstract][Full Text] [Related]
8. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.
Michaud K; Messer J; Choi HK; Wolfe F
Arthritis Rheum; 2003 Oct; 48(10):2750-62. PubMed ID: 14558079
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
Hsieh PH; Wu O; Geue C; McIntosh E; McInnes IB; Siebert S
Ann Rheum Dis; 2020 Jun; 79(6):771-777. PubMed ID: 32245893
[TBL] [Abstract][Full Text] [Related]
10. The costs of rheumatoid arthritis.
Allaire SH; Prashker MJ; Meenan RF
Pharmacoeconomics; 1994 Dec; 6(6):513-22. PubMed ID: 10155281
[TBL] [Abstract][Full Text] [Related]
11. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists?
Gabriel SE; Wagner JL; Zinsmeister AR; Scott CG; Luthra HS
Arthritis Rheum; 2001 Jul; 44(7):1504-14. PubMed ID: 11465700
[TBL] [Abstract][Full Text] [Related]
12. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
13. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
[TBL] [Abstract][Full Text] [Related]
15. Burden of rheumatoid arthritis from a societal perspective: A prevalence-based study on cost of this illness for patients in China.
Hu H; Luan L; Yang K; Li SC
Int J Rheum Dis; 2018 Aug; 21(8):1572-1580. PubMed ID: 28211251
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and out-patient medical costs of comorbid conditions in patients with rheumatoid arthritis.
Osiri M; Sattayasomboon Y
Joint Bone Spine; 2013 Dec; 80(6):608-12. PubMed ID: 23827409
[TBL] [Abstract][Full Text] [Related]
17. [A multicenter cross-sectional study on the health related quality of life of patients with rheumatoid arthritis using a revised Japanese version of the arthritis impact measurement scales version 2 (AIMS 2), focusing on the medical care costs and their associative factors].
Hashimoto A; Sato H; Nishibayahi Y; Shiino Y; Kutsuna T; Ishihara Y; Hoshi K; Fujimori J; Tsuboi S; Kondo H; Akizuki M; Moroi Y; Yoshida S
Ryumachi; 2002 Feb; 42(1):23-39. PubMed ID: 11925904
[TBL] [Abstract][Full Text] [Related]
18. Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.
Guillemin F; Durieux S; Daurès JP; Lafuma A; Saraux A; Sibilia J; Bourgeois P; Sany J
J Rheumatol; 2004 Jul; 31(7):1297-304. PubMed ID: 15229947
[TBL] [Abstract][Full Text] [Related]
19. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
[TBL] [Abstract][Full Text] [Related]
20. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
